DCIK细胞用于肺癌临床免疫治疗  

The Clinical Research of Cytokine-induced Killer Cells Co-culturing with Autologous Dendritic Cells on the Clinical Immunotherapy for

作　　者：朱柠[1] 陈小东[1] 刘祥麟 张尚权[3] 

机构地区：[1]复旦大学附属华山医院呼吸科,上海200040 [2]中科英达生物技术有限公司,上海201318 [3]中国科学院上海生命科学研究所生物化学与细胞生物学研究所,上海200031

出　　处：《细胞生物学杂志》2008年第2期251-256,共6页Chinese Journal of Cell Biology

基　　金：上海市科委重大科技攻关计划资助项目(No.05D219311)~~

摘　　要：观察细胞因子诱导的杀伤细胞(CIK细胞)和同源树突状细胞(DC)共培养后,共培养细胞树突状细胞调节的细胞因子诱导的杀伤细胞(DCIK细胞)体外细胞毒活性,并观察DCIK细胞治疗肺癌的近期临床疗效、免疫学活性及副反应。收录12例确诊肺癌经标准治疗方案治疗的患者,取外周血分离单个核细胞(PBMC),体外诱导出DC和CIK细胞共培养后,观察DCIK细胞表型,用MTT法测体外细胞毒活性;当效靶比为20∶1、10∶1时,DCIK细胞体外细胞毒活性杀伤率分别为55%、46.2%。所有患者均接受一定剂量的DCIK细胞过继免疫治疗,观察其近期临床疗效、免疫反应、不良反应。12例患者中完全缓解1例,部分缓解4例,病情稳定1例,近期有效率为41.6%,疾病控制率为50%,病情进展共6例,其中死亡2例。与DCIK细胞回输前相比,患者CD4+、CD8+、CD56+均有明显的升高(P<0.05),这表示可以诱导患者产生特异性的免疫反应。除两例患者出现一过性的发热外,其余患者基本无不良反应。DCIK细胞在肺癌免疫治疗中能诱导机体产生特异性的免疫反应,亦是新的杀伤肿瘤细胞的效应细胞,有较好的临床疗效。It’s to investigate the cytotoxicity in vitro of cytokine-induced killer （CIK） cells after coculturing with autologous dendritic cells （DCs）, and to observe their clinical antitumour efficacy, immunological activity, and side effects. Peripheral blood mononuclear cells （PBMC） were isolated from 12 patients with lung cancer, who had been treated with standard protocol. DCs and CIK cells were induced in vitro, then we determined the phenotype of cytokine-induced killer cells co-culturing with autologous dendritic cells （DCIK cells） and the cytotoxicity through MTT assay; when the ratios were 20∶1, 10∶1, the lysis ratios of DCIK cells were relatively 55%, 46.2%. All the patients were treated with a certain dosage of DCIK cells for immunotherapy, and we evaluated their clinical antitumour efficacy, immunological activity and side effects. Among the 12 patients, 1 patient got complete response, 4 patients got partial response and 1 patient got stable disease, so the recent clinical efficacy rate is 41.6%, and the rate of disease control is 50%. The other 6 patients got disease progressed, including that 2 patients died. The ratios of CD4^＋, CD8^＋, CD56^＋ significantly increased （P〈0.05）, comparing with ratios before DCIK cells infusion, which showed it could induce specific immunoreaction. No patient got side effect other than 2 patients who took a brief sensation of heat. DCIK cells is a new kind of killer cells , which could induce specific immunoreaction, and it could get better clinical efficacy.

关 键 词：树突状细胞 细胞因子诱导的杀伤细胞 肺癌 过继免疫治疗 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]